Complexity of ranolazine and phenytoin use in an infant with long QT syndrome type 3

Complexity of ranolazine and phenytoin use in an infant with long QT syndrome type 3

Bibliographic Details
Main Authors:	Reina Bianca Tan, MD, Sujata Chakravarti, MD, Melissa Busovsky-McNeal, MD, Abigail Walsh, NP, Frank Cecchin, MD
Format:	Article
Language:	English
Published:	Elsevier 2017-01-01
Series:	HeartRhythm Case Reports
Subjects:	Long QT Ranolazine Sodium channel Pharmacology Phenytoin Torsades de pointes
Online Access:	http://www.sciencedirect.com/science/article/pii/S221402711630121X

Similar Items

Ranolazine as an Alternative Therapy to Flecainide for SCN5A V411M Long QT Syndrome Type 3 Patients
by: Jordi Cano, et al.
Published: (2020-12-01)

Einfluss von Ranolazin und Flunarizin in Kombination mit d-Sotalol auf getriggerte Arrhythmien im isolierten Kaninchenherzen
by: Wallisch, Nora
Published: (2017)

Ranolazine: Multifaceted role beyond coronary artery disease, a recent perspective
by: Gopal Chandra Ghosh, et al.
Published: (2018-01-01)

Effects of Cardiac Resynchronization Therapy on the Arrhythmic Substrate in a Patient with Long QT and Torsades de pointes
by: Masayasu Ikutomi, MD, et al.
Published: (2011-01-01)

Landiolol suppression of electrical storm of torsades de pointes in patients with congenital long-QT syndrome type 2 and myocardial ischemia
by: Ryota Kitajima, MD, et al.
Published: (2017-10-01)

Long QT syndrome: A therapeutic challenge
by: Shah Maully, et al.
Published: (2008-01-01)

Is the Pleotropic Effect of Ranolazine is Due to its Antioxidant Action
by: Janapati Rama Krishna, et al.
Published: (2016-03-01)

A Case of Ciprofloxacin-Induced QT Prolongation and Torsade de Pointes
by: Hedieh Keshavarz-Bahaghighat, et al.
Published: (2017-09-01)

Proton Dependent Inhibition of the Cardiac Sodium Channel Nav1.5 by Ranolazine
by: Stanislav eSokolov, et al.
Published: (2013-06-01)

A hosszú-QT-szindróma és a torsades de pointes kamrai tachycardia története Historical overview of long-QT syndrome and torsades de pointes ventricular tachycardia
by: Fazekas Tamás, Prof. Dr
Published: (2012-12-01)

Ações Transmurais Inotrópicas e Antiarrítmicas da Ranolazina em um Modelo Celular da Síndrome do QT Longo Tipo 3
by: Victor Martins Miranda, et al.

Acquired long QT syndrome and Torsades de Poin
by: Ahmet Seyfeddin Gurbuz, et al.
Published: (2016-09-01)

Suppression of cardiac memory–related severe form of torsades de pointes by landiolol in a patient with congenital long QT syndrome type 2
by: Sou Otsuki, MD, PhD, et al.
Published: (2020-07-01)

The congenital long QT syndrome Type 3: An update
by: Andrés Ricardo Pérez-Riera, et al.
Published: (2018-01-01)

A case of hypoglycemiainduced QT prolongation leading to torsade de pointes and a review of pathophysiological mechanisms
by: Faris Hannoodi, et al.
Published: (2017-06-01)

Ranolazine: a Potential Anti-diabetic Drug
by: Li, Xiaoxiao
Published: (2013)

Electrical storm treated successfully in a patient with TANGO2 gene mutation and long QT syndrome: A case report
by: Frederico Scuotto, MD, CEPS-AC, et al.
Published: (2020-05-01)

A case of vasospastic angina. Vasospasm physiopathology: a new therapeutic role for ranolazine?
by: Carlo Uran, et al.
Published: (2020-08-01)

LONG QT SYNDROME. PART 2
by: Kalatsei L. V., et al.
Published: (2018-11-01)

The effect of ranolazine on maintaining sinus rhythm in patients with resistant atrial fibrillation
by: Fausto Devecchi, et al.
Published: (2008-08-01)

Efficacy of ranolazine in preventing atrial fibrillation following cardiac surgery: Results from a meta-analysis
by: Chintan Trivedi, MD, MPH, et al.
Published: (2017-06-01)

Síndrome de QT largo congénito
by: Luis Melgar Quicaño, et al.
Published: (2021-03-01)

Successful prenatal management of ventricular tachycardia and second-degree atrioventricular block in fetal long QT syndrome
by: Akira Miyake, MD, et al.
Published: (2017-01-01)

Frequency, characteristics and risk factors of QT interval prolonging drugs and drug-drug interactions in cancer patients: a multicenter study
by: Qasim Khan, et al.
Published: (2017-12-01)

QT Prolongation in Cancer Patients
by: Peter Kim, et al.
Published: (2021-02-01)

Mexiletine shortens the QT interval in a pedigree of KCNH2 related long QT syndrome
by: Taishi Fujisawa, et al.
Published: (2020-02-01)

RANOLAZINE IN ISCHEMIC HEART DISEASE
by: V. P. Lupanov
Published: (2015-12-01)

Extended-release ranolazine: critical evaluation of its use in stable angina
by: Melloni C, et al.
Published: (2011-08-01)

Torsades de Pointes associated with QT prolongation after catheter ablation of paroxysmal atrial fibrillation
by: Yae Min Park, et al.
Published: (2017-09-01)

Pharmacokinetic study of ranolazine in Chinese healthy volunteers
by: YU Mingjie, et al.
Published: (2019-01-01)

Medicamentos que podem induzir prolongamento do intervalo QT utilizados por idosos em domicílio
by: Josiane Macêdo Martins, et al.
Published: (2015-04-01)

QT prolongation and torsades de pointes during emergency treatment with nifekalant for refractory ventricular tachyarrhythmias: Post-hoc analysis from a large-scale multicenter post-marketing survey in Japan
by: Takao Katoh, MD, et al.
Published: (2013-10-01)

Place of the novel drug ranolazine in the treatment of coronary artery disease
by: GA Baryshnikova, et al.
Published: (2014-12-01)

Mechanical effects of ranolazine on normal and diabetic-isolated rat heart
by: Hajar Khazraei, et al.
Published: (2021-01-01)

Possible Interaction between Dabigatran and Ranolazine in Patients with Renal Failure
by: Gintautas Gumbrevičius, et al.
Published: (2019-12-01)

Antiarrhythmic Effect of Ranolazine in Combination with Selective NCX-Inhibition in an Experimental Model of Atrial Fibrillation
by: Julian Wolfes, et al.
Published: (2020-10-01)

Single dose oral ranolazine pharmacokinetics in patients receiving maintenance hemodialysis
by: Bridget A. Scoville, et al.
Published: (2019-01-01)

Long QT in stunned myocardium: unrecognised cause of acquired long QT syndrome
by: Jerzy Sacha
Published: (2014-09-01)

Genetic and Molecular Aspects of Drug-Induced QT Interval Prolongation
by: Daniela Baracaldo-Santamaría, et al.
Published: (2021-07-01)

Long QT Syndrome: A Clinical Entity Resembling Epilepsy
by: Mehmet Güney Şenol, et al.
Published: (2008-06-01)